LNSR · Lensar, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $58.44M | $53.49M | $42.16M | $35.36M | $34.46M | $26.38M |
| Cost of Revenue | $31.31M | $27.64M | $21.06M | $15.40M | $16.63M | $12.31M |
| Gross Profit | $27.12M | $25.85M | $21.11M | $19.95M | $17.83M | $14.07M |
| R&D | $5.62M | $5.33M | $6.14M | $11.81M | $12.36M | $7.55M |
| SG&A | $45.16M | $26.49M | $26.10M | $27.17M | $23.89M | $23.77M |
| Total Operating Expenses | $51.70M | $36.52M | - | - | - | - |
| D&A | $3.58M | $2.96M | $2.42M | $2.26M | $1.52M | $1.31M |
| Operating Income | ($24.58M) | ($10.66M) | ($12.23M) | ($20.18M) | ($19.65M) | ($18.50M) |
| Interest Expense | - | - | - | - | - | $1.34M |
| Income Tax | - | - | - | - | - | - |
| Net Income | ($34.28M) | ($31.40M) | ($14.38M) | ($19.91M) | ($19.60M) | ($19.77M) |
| EPS - Basic | ($2.87) | ($2.73) | ($1.31) | ($1.96) | - | - |
| EPS - Diluted | ($2.87) | ($2.73) | ($1.31) | ($2.09) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.97M | $16.26M | $20.62M | $14.67M | $31.64M | $4.62M |
| Accounts Receivable | $6.38M | $6.08M | $4.00M | $6.04M | $4.64M | $2.01M |
| Inventory | $21.52M | $11.43M | $15.69M | $11.74M | $6.49M | $13.47M |
| Accounts Payable | $18.98M | $6.00M | $4.01M | $5.42M | $2.69M | $2.48M |
| Current Assets | $46.77M | $41.98M | $46.44M | $33.72M | $44.81M | $58.38M |
| Total Assets | $71.43M | $66.30M | $69.58M | $55.84M | $66.47M | $79.12M |
| Current Liabilities | $40.57M | $15.00M | $11.63M | $11.42M | $8.71M | $8.47M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $83.67M | $47.65M | $22.41M | $13.86M | $11.59M | $11.91M |
| Stockholders' Equity | ($26.02M) | $4.86M | $33.43M | $41.98M | $54.88M | $67.21M |
| Retained Earnings | ($177.57M) | ($143.29M) | ($111.89M) | ($97.51M) | ($77.59M) | ($57.99M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($14.83M) | ($2.27M) | ($9.66M) | ($14.86M) | ($8.97M) | ($13.79M) |
| Investing Cash Flow | $1.28M | ($2.16M) | ($4.16M) | ($115.0K) | ($354.0K) | ($326.0K) |
| Financing Cash Flow | $10.26M | $78.0K | $19.76M | ($1.99M) | $361.0K | $50.00M |
| CapEx | $83.0K | $156.0K | $236.0K | $115.0K | $354.0K | $366.0K |
| Free Cash Flow | ($14.91M) | ($2.43M) | ($9.89M) | ($14.97M) | ($9.32M) | ($14.16M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 46.4% | 48.3% | 50.1% | 56.4% | 51.8% | 53.4% |
| Operating margin | -42.1% | -19.9% | -29.0% | -57.1% | -57.0% | -70.1% |
| EBITDA margin | -35.9% | -14.4% | -23.3% | -50.7% | -52.6% | -65.2% |
| Net margin | -58.7% | -58.7% | -34.1% | -56.3% | -56.9% | -75.0% |
| Free cash flow margin | -25.5% | -4.5% | -23.5% | -42.3% | -27.1% | -53.7% |
| FCF / Net income | 0.44 | 0.08 | 0.69 | 0.75 | 0.48 | 0.72 |
| R&D / Revenue | 9.6% | 10.0% | 14.6% | 33.4% | 35.9% | 28.6% |
| SG&A / Revenue | 77.3% | 49.5% | 61.9% | 76.8% | 69.3% | 90.1% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -48.0% | -47.4% | -20.7% | -35.7% | -29.5% | -25.0% |
| Return on equity | 131.7% | -645.9% | -43.0% | -47.4% | -35.7% | -29.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.15 | 2.80 | 3.99 | 2.95 | 5.14 | 6.90 |
| Quick ratio | 0.62 | 2.04 | 2.64 | 1.92 | 4.40 | 5.30 |
| Cash ratio | 0.32 | 1.08 | 1.77 | 1.28 | 3.63 | 0.55 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | -13.8x |
| Equity multiplier | -2.75 | 13.64 | 2.08 | 1.33 | 1.21 | 1.18 |
| Liabilities / Assets | 1.17 | 0.72 | 0.32 | 0.25 | 0.17 | 0.15 |
| Efficiency | ||||||
| Asset turnover | 0.82 | 0.81 | 0.61 | 0.63 | 0.52 | 0.33 |
| Inventory turnover | 1.46 | 2.42 | 1.34 | 1.31 | 2.56 | 0.91 |
| Days sales outstanding | 40d | 42d | 35d | 62d | 49d | 28d |
| Days inventory outstanding | 251d | 151d | 272d | 278d | 142d | 400d |
| Days payable outstanding | 221d | 79d | 69d | 128d | 59d | 74d |
| Cash conversion cycle | 69d | 113d | 237d | 212d | 132d | 354d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | 21.2x | 1.2x | 0.7x | - | - |
| P / S | 2.4x | 1.9x | 0.9x | 0.8x | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 9.2% | 26.9% | 19.2% | 2.6% | 30.6% | - |
| Revenue CAGR (3y) | 18.2% | 15.8% | 16.9% | - | - | - |
| Revenue CAGR (5y) | 17.2% | - | - | - | - | - |
| Gross profit growth (YoY) | 4.9% | 22.5% | 5.8% | 11.9% | 26.7% | - |
| Operating income growth (YoY) | -130.5% | 12.8% | 39.4% | -2.7% | -6.2% | - |
| Net income growth (YoY) | -9.2% | -118.3% | 27.8% | -1.6% | 0.9% | - |
| EPS growth (YoY) | -5.1% | -108.4% | 37.3% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -513.5% | 75.4% | 33.9% | -60.6% | 34.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -85.5% | -20.4% | -23.5% | -18.3% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$51.66M totalProduct$45.93M · 88.9%
Service$5.73M · 11.1%
Geographic
$51.66M totalUS$34.31M · 66.4%
Europe$8.43M · 16.3%
Asia Excluding South Korea$8.02M · 15.5%
KR$658.0K · 1.3%
Other Geographical Region$238.0K · 0.5%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-2.43
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing LENSAR against the 5 most active filers in the same SIC group.